Merck Asks FDA Emergency Authorization For Experimental COVID-19 Pill
Umer Jamshaid Published October 11, 2021 | 06:40 PM
WASHINGTON (UrduPoint News / Sputnik - 11th October, 2021) American pharmaceutical company Merck & Co said on Monday that it has requested emergency approval from the US drug regulator for its antiviral COVID-19 treatment.
On October 1, the pharmaceutical giant announced a successful trial of molnupiravir, which reduces the risk of hospitalization and death from COVID-19 by 50%.
"Merck has submitted an Emergency Use Authorization (EUA) application to the U.S. food and Drug Administration (FDA) for molnupiravir, an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressive to severe COVID-19 and/or hospitalization," the company said.
If approved, the pill, which Merck developed with Ridgeback Biotherapeutics, would be the first COVID-19 oral drug approved by the FDA.
"At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%," the statement read.
An interim analysis of a phase 3 study found that 7.3% of patients treated with molnupiravir were hospitalized within 29 days. Of the patients who received a placebo, 14.1% were hospitalized or had died by day 29. No deaths were reported among patients who were given molnupiravir within the 29-day period, while eight deaths were reported in placebo-treated patients.
All 775 trial participants had laboratory-confirmed symptoms of COVID-19, and molnupiravir or a placebo were randomly administered within five days of symptoms, the statement said.
Adverse events were comparable in the molnupiravir and placebo groups, with around 10% reporting adverse events. Just 1.3% of the molnupiravir group discontinued therapy due to an adverse event � less than the 3.4% of the placebo group who did so.
Participants were unvaccinated and had at least one underlying factor that put them at greater risk of developing a more severe case of the virus. The most common risk factors included obesity, age over 60, diabetes or heart disease.
Molnupiravir's efficacy was not affected by the timing of symptom onset or patients' underlying risk factors, the study showed. It also proved to be consistently effective in treating all COVID-19 variants, including the widely dominant and highly transmissible delta strain.
The trial was conducted at more than 170 locations, in countries including the United States, Canada, the United Kingdom, Brazil, Italy, Japan, South Africa, Spain, Ukraine, and Guatemala.
Related Topics
Recent Stories
Usain Bolt named ICC Men’s T20 World Cup 2024 Ambassador
PM visits martyred Customs official's residence in Abbottabad
Punjab CM Maryam faces legal case for wearing police uniform
PTDC plans to organize two-day tourism expo
COP29 host says deal on climate aid essential but offers few details
SC orders end of encroachments in Karachi
Nazish Jahangir denies viral screenshots, calls them fake
Govt likely to hike electricity price once again
Bismah Maroof announces immediate retirement from international cricket
Malala expresses unwavering support for Gaza people
Selection committee dissolved over Pakistan women cricket team's poor performanc ..
Punjab CM Maryam Nawaz in police uniform at Chung police center
More Stories From World
-
COP29 host says deal on climate aid essential but offers few details
15 minutes ago -
Ukraine jails couple for helping Russia strike hospital
28 minutes ago -
Togo opposition asks W.Africa court to overturn reforms
38 minutes ago -
Paris landmark Moulin Rouge's windmill sails collapse
58 minutes ago -
Ahead of feared Rafah invasion, Palestinians mourn bombardment dead
58 minutes ago -
155 killed in Tanzania as heavy rains cause floods, landslides: PM
58 minutes ago
-
Car giants vie for EV crown at Beijing's Auto China show
58 minutes ago -
Chinese defense minister to attend SCO meeting in Kazakhstan
1 hour ago -
China-Bangladesh to hold joint military exercise in May
1 hour ago -
Residents protest as Venice launches five-euro entry fee
1 hour ago -
Portugal marks 50 years of democracy with far right on rise
2 hours ago -
Pakistan envoy visits TomatoWorld in Netherlands
2 hours ago